RTGN RetinalGenix Technologies Inc.
Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1836295 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY26.9%
TTM EPS YoY33.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-34,441.5%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets46,768.1%
Debt / equity—
Current ratio0.00x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.23x
Accruals ratio-26,393.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $83,040 | $373,271 |
| SG&A expense | $1.30M | $1.33M |
| Interest expense | $4,005 | $3,840 |
| Net income | -$2.43M | -$4.32M |
| EPS (basic) | -0.13 | -0.24 |
| EPS (diluted) | -0.13 | -0.24 |
| Weighted avg. shares (diluted) | 18.56M | 17.94M |
| Balance sheet | ||
| Cash & equivalents | $14,774 | $6,060 |
| Current assets | $14,774 | $6,060 |
| PP&E, net | — | $56 |
| Total assets | $21,041 | $14,946 |
| Current liabilities | $2.32M | $1.47M |
| Total liabilities | $2.32M | $1.48M |
| Shareholders' equity | -$2.30M | -$1.46M |
| Shares outstanding | 18.75M | 18.52M |
| Cash flow statement | ||
| Operating cash flow | -$558,350 | -$741,936 |
| Financing cash flow | $567,064 | $747,996 |
| Depreciation & amortization | $56 | $100 |
| Stock-based compensation | $1.04M | $2.61M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.